

## Press Release

**Matthias Link**  
Corporate Communications

Fresenius SE  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 608-2872  
F +49 6172 608-2294  
matthias.link@fresenius.com  
www.fresenius.com

October 28, 2009

### **Fresenius Kabi and Octapharma Group enter into an Exclusive License, Development and Supply Agreement for a HESylated recombinant protein**

Fresenius Kabi and Octapharma Group have signed a License, Development and Supply Agreement regarding the use of Fresenius Kabi's HESylation® Technology to develop a HESylated recombinant protein.

Under the agreement, Fresenius Kabi will license its proprietary HESylation® Technology to Octapharma. This technology platform is based on hydroxyethyl starch ("HES") which will be combined with a recombinant protein from Octapharma's human cell-line platform – this combination is intended to generate a therapeutic protein with a superior product profile.

Fresenius Kabi will seek to adapt and optimize the protein modification by its HESylation® Technology and will afterwards be responsible for providing the appropriate HES derivative to Octapharma. Under the agreement, Octapharma will oversee the further development and commercialization. Fresenius Kabi will receive up-front and milestone payments, research funding and royalties on sales for licensing of the HESylation® Technology.

Fresenius Kabi expects to enter into further collaborations with leading pharmaceutical and biotechnology companies to contribute to improved pharmaceutical products through its HESylation® Technology platform.

## **HESylation® Technology**

HESylation® Technology is based on the extensive expertise in the field of hydroxyethyl starch ("HES") that Fresenius Kabi has gathered as the world's largest producer of pharmaceutical grade HES. HES is derived from waxy maize starch and can be metabolized by the body's enzymes. HES solutions have been safely administered for over 30 years to treat deficient blood volume and to improve the rheological properties of blood.

HESylation® Technology allows a targeted modification of drugs and their characteristics by a site-specific coupling to HES molecules. This can modify key pharmacological parameters such as absorption, metabolism, half-life, water solubility and safety.

HESylation® Technology is covered by a broad portfolio of intellectual property rights. For further details please visit <http://www.HESylation.com>.

# # #

## **Fresenius Kabi**

Fresenius Kabi is focused on products for the therapy and care of critically and chronically ill patients in and outside the hospital. Fresenius Kabi's core product range includes infusion solutions for fluid substitution, blood volume substitution and intravenously administered drugs as well as parenteral and enteral nutrition and the medical devices for the application.

Fresenius Kabi has more than 20,000 employees worldwide and a global network of around 55 sales organizations and more than 55 production sites. In 2008, Fresenius Kabi achieved sales of € 2,495 million and an operating profit (EBIT) of € 443 million. Fresenius Kabi AG is a 100% subsidiary of the health care group Fresenius SE.

For more information about Fresenius Kabi, please visit the company's web site at [www.fresenius-kabi.com](http://www.fresenius-kabi.com)

Contact for HESylation®:  
Frank Feller, Commercial Affairs & Business Development  
Kabi Innovation Centre  
Fresenius Kabi Deutschland GmbH  
T: +49 6172 686 8558  
F: +49 6172 686 390033  
Email: [hesylation@fresenius-kabi.com](mailto:hesylation@fresenius-kabi.com)  
[www.HESylation.com](http://www.HESylation.com)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Rainer Baule (Chairman), Marc Crouton, John Ducker, Mats Henriksson, Manfred M. Köhler, Dr. Michael Schönhofen, Thomas H. Silberg, Gerrit Steen  
Chairman of the Supervisory Board: Dr. Ulf M. Schneider  
Registered Office: Bad Homburg, Germany/Commercial Register: Amtsgericht Frankfurt am Main - HRB 45881

## **About Octapharma Group**

The Octapharma Group is an independent, Swiss-based biopharmaceutical company operating worldwide. Octapharma's core business is the development, production, and sale of high-quality human proteins for the treatment of life-threatening diseases.

The Group has more than 3,000 employees in 28 countries, and owns five modern, state-of-the-art production facilities in Austria, France, Germany, Sweden, and Mexico, respectively. Sales turnover in 2008 reached € 886 million with an EBIT of € 256 million.

For more information about Octapharma Group please visit the company's website:

[www.octapharma.com](http://www.octapharma.com)